Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA

World Journal of Gastroenterology

Volumn 17, Issue 24, 2011, Pages 2924-2932

  Yeh, Chun Nan ^a   Lin, Kun Ju ^a   Chen, Tsung Wen ^a   Wu, Ren Ching ^a   Tsao, Lee Cheng ^b   Chen, Ying Tzu ^b   Weng, Wen Hui ^b   Chen, Miin Fu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

Author keywords

Characterization; Cholangiocarcinoma; Establishment; Rat cell line; Thioacetamide

Indexed keywords

CYCLOOXYGENASE 2; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; K RAS PROTEIN; MUCIN 4; THIOACETAMIDE;

ANIMAL CELL; ARTICLE; AUTORADIOGRAPHY; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CARCINOGENICITY; CULTURE MEDIUM; DIPLOIDY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PHENOTYPE; RAT; SPECTRAL KARYOTYPING; TUMOR XENOGRAFT;

EID: 79959643164     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i24.2924     Document Type: Article

References (42)

1. Liver Cancer Study Group of Japan. Classification of primary liver cancer. 1st English ed. Tokyo: Kanehara Shuppan, 1997
2. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001; 193: 384-391
3. Uenishi T, Hirohashi K, Kubo S, Yamamoto T, Hamba H, Tanaka H, Kinoshita H. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg 2001; 25: 865-869
4. Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-517; discussion 517-519
5. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999; 341: 1368-1378
6. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357
7. Shirabe K, Shimada M, Harimoto N, Sugimachi K, Yamashita Y, Tsujita E, Aishima S. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery 2002; 131: S159-S164
8. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125
9. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40: 472-477
10. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10
11. Chang KY, Chang JY, Yen Y. Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw 2009; 7: 423-427
12. Yeh CN, Maitra A, Lee KF, Jan YY, Chen MF. Thioacetamideinduced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 2004; 25: 631-636
13. Lai GH, Sirica AE. Establishment of a novel rat cholangiocarcinoma cell culture model. Carcinogenesis 1999; 20: 2335-2340
14. Yeh CN, Pang ST, Chen TW, Wu RC, Weng WH, Chen MF. Expression of ezrin is associated with invasion and dedifferentiation of hepatitis B related hepatocellular carcinoma. BMC Cancer 2009; 9: 233
15. Weng WH, Wejde J, Ahlén J, Pang ST, Lui WO, Larsson C. Characterization of large chromosome markers in a malignant fibrous histiocytoma by spectral karyotyping, comparative genomic hybridization (CGH), and array CGH. Cancer Genet Cytogenet 2004; 150: 27-32
16. Shaffer LG, Tommerup N. An international system for human cytogenetic nomenclature. Basel: S. Karger, 2005
17. Fritscher-Ravens A, Bohuslavizki KH, Broering DC, Jenicke L, Schäfer H, Buchert R, Rogiers X, Clausen M. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 2001; 22: 1277-1285
18. Yeh CN, Lin KJ, Hsiao IT, Yen TC, Chen TW, Jan YY, Chung YH, Lin CF, Chen MF. Animal PET for thioacetamide-induced rat cholangiocarcinoma: a novel and reliable platform. Mol Imaging Biol 2008; 10: 209-216
19. Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol 1999; 14: 1144-1149
20. Bartlett DL. Intrahepatic cholangiocarcinoma: a worthy challenge. Cancer J 2009; 15: 255-256
21. Tengchaisri T, Prempracha N, Thamavit W, Boonpucknavig S, Sriurairatana S, Sirisinha S. Establishment and characterization of cell lines from liver fluke-associated cholangiocarcinoma induced in a hamster model. Southeast Asian J Trop Med Public Health 1995; 26: 231-239
22. Sirica AE. Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis. Toxicol Pathol 1996; 24: 90-99
23. Jan YY, Yeh TS, Yeh JN, Yang HR, Chen MF. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Ann Surg 2004; 240: 89-94
24. Yamaguchi N, Morioka H, Ohkura H, Hirohashi S, Kawai K. Establishment and characterization of the human cholangiocarcinoma cell line HChol-Y1 in a serum-free, chemically defined medium. J Natl Cancer Inst 1985; 75: 29-35
25. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol 1989; 25: 503-510
26. Sirisinha S, Tengchaisri T, Boonpucknavig S, Prempracha N, Ratanarapee S, Pausawasdi A. Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer. Asian Pac J Allergy Immunol 1991; 9: 153-157
27. Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, Iwatsuki S, Herberman RB, Whiteside TL. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 1992; 52: 252-260
28. Elmore LW, Sirica AE. "Intestinal-type" of adenocarcinoma preferentially induced in right/caudate liver lobes of rats treated with furan. Cancer Res 1993; 53: 254-259
29. Radaeva S, Ferreira-Gonzalez A, Sirica AE. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 1999; 29: 1453-1462
30. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002; 13: 41-59
31. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 1998; 29: 175-180
32. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002; 36: 439-450
33. Hansel DE, Rahman A, Hidalgo M, Thuluvath PJ, Lillemoe KD, Shulick R, Ku JL, Park JG, Miyazaki K, Ashfaq R, Wistuba II, Varma R, Hawthorne L, Geradts J, Argani P, Maitra A. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 2003; 163: 217-229
34. Sirica AE, Lai GH, Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 2001; 16: 363-372
35. Muller D, Zimmerman SI, Schiller F. Drug metabolism in rat liver injured by thioacetamide. Arch Toxicol 1982; 5: 368-371
36. Dashti HM, Mathew TC, Jadaon MM, Ashkanani E. Zinc and liver cirrhosis: biochemical and histopathologic assessment. Nutrition 1997; 13: 206-212
37. Yeh CN, Pang ST, Wu RC, Chen TW, Jan YY, Chen MF. Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy. Oncol Rep 2009; 21: 49-56
38. Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C, Marshall CJ. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991; 51: 3497-3502
39. Xu L, Hausmann M, Dietmaier W, Kellermeier S, Pesch T, Stieber-Gunckel M, Lippert E, Klebl F, Rogler G. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines. BMC Cancer 2010; 10: 302
40. Ohashi K, Tstsumi M, Nakajima Y, Nakano H, Konishi Y. Kiras point mutations and proliferation activity in biliary tract carcinomas. Br J Cancer 1996; 74: 930-935
41. Hidaka E, Yanagisawa A, Seki M, Takano K, Setoguchi T, Kato Y. High frequency of K-ras mutations in biliary duct carcinomas of cases with a long common channel in the papilla of Vater. Cancer Res 2000; 60: 522-524
42. Gisselsson D, Höglund M, Mertens F, Johansson B, Dal Cin P, Van den Berghe H, Earnshaw WC, Mitelman F, Mandahl N. The structure and dynamics of ring chromosomes in human neoplastic and non-neoplastic cells. Hum Genet 1999; 104: 315-325